Kura Oncology (KURA) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a research report released on Tuesday morning, Zacks.com reports. The brokerage currently has $19.00 target price on the stock.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Several other analysts have also recently weighed in on KURA. BidaskClub raised shares of Kura Oncology from a sell rating to a hold rating in a research note on Tuesday, May 7th. HC Wainwright set a $31.00 price objective on shares of Kura Oncology and gave the stock a buy rating in a research note on Wednesday, May 8th. ValuEngine raised shares of Kura Oncology from a hold rating to a buy rating in a research note on Wednesday, March 27th. Finally, Oppenheimer reaffirmed a buy rating on shares of Kura Oncology in a research note on Tuesday, March 19th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Kura Oncology presently has a consensus rating of Buy and a consensus price target of $28.40.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.08. As a group, equities analysts anticipate that Kura Oncology will post -1.77 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its stake in shares of Kura Oncology by 46.9% during the third quarter. Wells Fargo & Company MN now owns 42,222 shares of the company’s stock valued at $739,000 after purchasing an additional 13,489 shares during the last quarter. Fosun International Ltd bought a new stake in shares of Kura Oncology during the fourth quarter valued at approximately $2,643,000. Rhumbline Advisers grew its stake in shares of Kura Oncology by 59.1% during the fourth quarter. Rhumbline Advisers now owns 37,118 shares of the company’s stock valued at $521,000 after purchasing an additional 13,781 shares during the last quarter. MetLife Investment Advisors LLC grew its stake in shares of Kura Oncology by 111.6% during the third quarter. MetLife Investment Advisors LLC now owns 21,375 shares of the company’s stock valued at $374,000 after purchasing an additional 11,273 shares during the last quarter. Finally, Prosight Management LP grew its stake in shares of Kura Oncology by 24.8% during the fourth quarter. Prosight Management LP now owns 316,581 shares of the company’s stock valued at $4,445,000 after purchasing an additional 62,950 shares during the last quarter. 85.47% of the stock is currently owned by institutional investors and hedge funds.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Article: What is an overbought condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.